| Prev Close | 173.67 |
| Open | 173.02 |
| Day Low/High | 172.42 / 173.92 |
| 52 Wk Low/High | 130.09 / 181.81 |
| Volume | 705.81K |
| Avg Volume | 3.49M |
| Exchange | NASDAQ |
| Shares Outstanding | 735.40M |
| Market Cap | 126.86B |
| EPS | 10.30 |
| P/E Ratio | 16.38 |
| Div & Yield | 4.60 (2.70%) |
Latest News
Biotech Movers: Regeneron Slides Back After Big Gains
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
Dems Roast Trump for Leaving Medicare Out of Drug Price Order
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Amgen Defends Drug Pipeline, Says the Best is Yet to Come
Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.
Amgen To Present New Data At 22nd Congress Of The European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
FDA Sets PDUFA Target Action Date of Feb. 3, 2018
Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags
Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.
Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting Of The American Headache Society
Data From Broad Clinical Program Show Investigational Erenumab is Effective at Preventing Migraine in Patients Experiencing Four or More Migraine Days a Month
With Solid Base, Amgen Keeps Climbing
The stock is set up well for more upside and remains very near a low-risk buy zone.
Amgen Wants to Boost Label on Powerhouse Repatha
The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.
Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe
Applications Based on Data From Repatha Cardiovascular Outcomes Study Showing an Additional Reduction in Heart Attacks, Strokes and Coronary Revascularizations on Top of Optimized Statin Therapy
Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid
Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor
Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge
Massachusetts Governor Charles Baker and U.S. Senator Edward Markey Join Members of the Life Sciences Community at Newly Expanded Facility in Kendall Square
Intermediate Trade: QQQ
The tactic is the bearishly biased, calendar diagonal call spread, which controls the risk of the trade.
Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In
Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.
Biotech Movers: Radius Health, Amgen, Paratek
Radius Health, Amgen and Paratek Pharmaceuticals were among the biotech movers in premarket trading on Monday.
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV
UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen
Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis
ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures
Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets
New Analysis From Cardiovascular Outcomes Trial Shows Addition of Repatha in Patients Considered at Goal Further Reduces Cardiovascular Event Risk
